Modeling Lewy body disease with SNCA triplication iPSC-derived cortical organoids and identifying therapeutic drugs
Science Advances · 2024
DOI: 10.1126/sciadv.adk3700 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Yunjung Jin und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA. Hauptthemen laut MEDLINE: alpha-Synuclein, Organoids, Induced Pluripotent Stem Cells, Lewy Body Disease. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Aggregated α-synuclein (α-SYN) proteins, encoded by the SNCA gene, are hallmarks of Lewy body disease (LBD), affecting multiple brain regions. However, the specific mechanisms underlying α-SYN pathology in cortical neurons, crucial for LBD-associated dementia, remain unclear. Here, we recapitulated α-SYN pathologies in human induced pluripotent stem cells (iPSCs)–derived cortical organoids generated from patients with LBD with SNCA gene triplication. Single-cell RNA sequencing, combined with functional and molecular validation, identified synaptic and mitochondrial dysfunction in excitatory neurons exhibiting high expression of the SNCA gene, aligning with observations in the cortex of autopsy-confirmed LBD human brains. Furthermore, we screened 1280 Food and Drug Administration–approved drugs and identified four candidates (entacapone, tolcapone, phenazopyridine hydrochloride, and zalcitabine) that inhibited α-SYN seeding activity in real-time quaking-induced conversion assays with human brains, reduced α-SYN aggregation, and alleviated mitochondrial dysfunction in SNCA triplication organoids and excitatory neurons. Our findings establish human cortical LBD models and suggest potential therapeutic drugs targeting α-SYN aggregation for LBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
- Department of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, FL 32224, USA.
- Tygerberg Hospital and University of Stellenbosch, Tygerberg 7505, South Africa.
- Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA.
ORCID-Profile: Yunjung Jin, Fuyao Li, Zonghua Li, Tadafumi C Ikezu, Justin O'Leary, Yiyang Zhu, Yuka A Martens, Shunsuke Koga, Hannah Santhakumar, Yonghe Li, Yang You, Kiara Lolo, Michael DeTure, Alexandra I Beasley, Mary D Davis, Pamela J McLean, Owen A Ross, Takahisa Kanekiyo, Tsuneya Ikezu, Thomas Caulfield, Jonathan Carr, Zbigniew K Wszolek, Guojun Bu, Dennis W Dickson, Na Zhao
Förderung
- NIA NIH HHS
- NINDS NIH HHS
Zitieren
APA
Jin, Y., Li, F., Li, Z., Ikezu, T. C., O'Leary, J., Selvaraj, M., Zhu, Y., Martens, Y. A., Koga, S., Santhakumar, H., Li, Y., Lu, W., You, Y., Lolo, K., DeTure, M., Beasley, A. I., Davis, M. D., McLean, P. J., Ross, O. A., …, & Zhao, N. (2024). Modeling Lewy body disease with SNCA triplication iPSC-derived cortical organoids and identifying therapeutic drugs. Science Advances. https://doi.org/10.1126/sciadv.adk3700
Vancouver
Jin Y, Li F, Li Z, Ikezu TC, O'Leary J, Selvaraj M, et al. Modeling Lewy body disease with SNCA triplication iPSC-derived cortical organoids and identifying therapeutic drugs. Science Advances. 2024. doi:10.1126/sciadv.adk3700
BibTeX
@article{Jin2024,
author = {Jin, Yunjung and Li, Fuyao and Li, Zonghua and Ikezu, Tadafumi C and O'Leary, Justin and Selvaraj, Manikandan and Zhu, Yiyang and Martens, Yuka A and Koga, Shunsuke and Santhakumar, Hannah and Li, Yonghe and Lu, Wenyan and You, Yang and Lolo, Kiara and DeTure, Michael and Beasley, Alexandra I and Davis, Mary D and McLean, Pamela J and Ross, Owen A and Kanekiyo, Takahisa and Ikezu, Tsuneya and Caulfield, Thomas and Carr, Jonathan and Wszolek, Zbigniew K and Bu, Guojun and Dickson, Dennis W and Zhao, Na},
title = {Modeling Lewy body disease with SNCA triplication iPSC-derived cortical organoids and identifying therapeutic drugs},
journal = {Science Advances},
year = {2024},
doi = {10.1126/sciadv.adk3700}
}
EUVIMED